cancer vaccine Archives -

Targeting COVID-19 and cancer with immunotherapy advancements

News/ News/ News/ Oncology/ R&D

RhoVac pummelled as lead cancer vaccine fails study

Phil Taylor cancer vaccine, immuno-oncology, metastatic, Oncology, Prostate cancer, RhoVac 0 Comment

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase

RhoVac pummelled as lead cancer vaccine fails study

https://pharmaphorum.com/news/rhovac-pummelled-as-lead-cancer-vaccine-fails-study/

News/ News/ News/ Oncology/ R&D

Nykode vaccine shows its worth in cervical cancer trial

Phil Taylor cancer vaccine, cervical cancer, HPV, immuno-oncology, Nykode Therapeutics, Oncology, Vaccibody 0 Comment

Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds

Nykode vaccine shows its worth in cervical cancer trial

https://pharmaphorum.com/news/nykode-vaccine-shows-its-worth-in-cervical-cancer-trial/

Vaccine vial dose flu shot drug needle syringe,medical concept vaccination hypodermic injection treatment disease care hospital prevention immunization illness disease baby child.blue background

News/ News/ Oncology

Imugene HER2 vaccine hits target in stomach cancer trial

Phil Taylor Australia, Biotech, cancer vaccine, gastric cancer, immuno-oncology, Imugene, Oncology 0 Comment

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive

Imugene HER2 vaccine hits target in stomach cancer trial

https://pharmaphorum.com/news/imugene-her2-vaccine-hits-target-in-stomach-cancer-trial/

News/ News/ Oncology

BioNTech takes its first cancer vaccine into phase 2

Phil Taylor BioNTech, BNT111, cancer vaccine, immuno-oncology, melanoma, Oncology 0 Comment

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on

BioNTech takes its first cancer vaccine into phase 2

https://pharmaphorum.com/news/biontech-takes-its-first-cancer-vaccine-bnt111-into-phase-2/

News/ News/ Oncology

Belgium’s eTheRNA gets EU grant to develop mRNA cancer vaccines

Richard Staines BioNTech, cancer vaccine, eTheRNA, Pfizer, vaccine 0 Comment

Belgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development

Belgium’s eTheRNA gets EU grant to develop mRNA cancer vaccines

https://pharmaphorum.com/news/belgiums-etherna-gets-eu-grant-to-develop-mrna-cancer-vaccines/

News/ News/ Oncology

Roche pays $200m for Vaccibody’s cancer vaccine drug

Richard Staines cancer, cancer vaccine, R&D, Roche, Vaccibody 0 Comment

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which

Roche pays $200m for Vaccibody’s cancer vaccine drug

https://pharmaphorum.com/news/roche-pays-200m-for-vaccibodys/

News/ News/ News/ Oncology/ R&D

Regeneron pairs with BioNTech on melanoma immunotherapy

Phil Taylor BioNTech, cancer vaccine, checkpoint inhibitors, immuno-oncology, Libtayo, melanoma, Regeneron 0 Comment

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech

Regeneron pairs with BioNTech on melanoma immunotherapy

https://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/

Digital/ News/ News/ News/ News/ Oncology/ R&D

Transgene starts trials of ‘digital’ cancer vaccine with NEC

Phil Taylor cancer vaccine, head and neck cancer, ovarian cancer, Transgene 0 Comment

Undeterred by two clinical failures for its cancer immunotherapies in 2019, Transgene has kicked off the New Year

Transgene starts trials of ‘digital’ cancer vaccine with NEC

https://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/

News/ News/ News/ Oncology/ R&D/ Top stories

UK startup Ervaxx targets ‘dark matter’ of human genome

Phil Taylor cancer vaccine, cell therapy, Ervaxx, immuno-oncology, melanoma, UK 0 Comment

After two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing

UK startup Ervaxx targets ‘dark matter’ of human genome

https://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/

Trending

cancer vaccine

Login